



# Induction of DNA damages upon Marek's disease virus infection: implication in viral replication and pathogenesis

Djihad Bencherit, Sylvie Rémy, Yves Le Vern, Tereza Vychodil, Luca D. Bertzbach, Benedikt B. Kaufer, Caroline Denesvre, Laëtitia Trapp-Fragnet

## ► To cite this version:

Djihad Bencherit, Sylvie Rémy, Yves Le Vern, Tereza Vychodil, Luca D. Bertzbach, et al.. Induction of DNA damages upon Marek's disease virus infection: implication in viral replication and pathogenesis. Journal of Virology, 2017, 91 (24), 16 p. 10.1128/JVI.01658-17 . hal-02629179

**HAL Id: hal-02629179**

**<https://hal.inrae.fr/hal-02629179>**

Submitted on 27 May 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

1 **Induction of DNA damages upon Marek's disease virus infection: implication in viral**  
2 **replication and pathogenesis**

3

4 **Running title:** DNA damage upon MDV infection

5

6 Djihad Bencherit,<sup>a</sup> Sylvie Remy,<sup>a</sup> Yves Le Vern,<sup>b</sup> Tereza Vychodil,<sup>c</sup> Luca D. Bertzbach,<sup>c</sup>  
7 Benedikt B. Kaufer,<sup>c</sup> Caroline Denesvre,<sup>a</sup> and Laëtitia Trapp-Fragnet<sup>a</sup>

8

9 <sup>a</sup> INRA, UMR1282, Infectiologie et Santé Publique, Equipe Biologie des Virus Aviaires,  
10 Nouzilly, France

11 <sup>b</sup> INRA, UMR1282 Infectiologie et Santé Publique, Laboratoire de Cytométrie, Nouzilly,  
12 France

13 <sup>c</sup> Institut für Virologie, Freie Universitaet Berlin, Berlin, Germany

14

15

16 **Corresponding author:** Laëtitia Trapp-Fragnet, INRA, UMR1282, Infectiologie et Santé  
17 Publique, Equipe Biologie des Virus Aviaires, Nouzilly, France; Tel: +33 2 474 279 42;  
18 email: laetitia.trapp-fragnet@inra.fr

19

20 Abstract: 188 words / Importance: 134 words / Text: 5751 words

21 **ABSTRACT**

22 Marek's disease virus (MDV) is a highly contagious alphaherpesvirus that infects chickens  
23 and causes a deadly neoplastic disease. We previously demonstrated that MDV infection  
24 arrests cells in S-phase and that the tegument protein VP22 plays a major role in this process.  
25 In addition, expression of VP22 induces double strand breaks (DSB) in the cellular DNA,  
26 suggesting that DNA damage and the associated cellular response might be favorable for the  
27 MDV lifecycle. Here, we addressed the role of DNA damage in MDV replication and  
28 pathogenesis. We demonstrated that MDV induces DSB during lytic infection *in vitro* and in  
29 the PBMCs of infected animals. Intriguingly, we did not observe DNA damage in latently  
30 infected MDV-induced lymphoblastoid cells, while MDV reactivation resulted in the onset of  
31 DNA lesions, suggesting that DNA damage and/or the resulting DNA damage response might  
32 be required for efficient MDV replication and reactivation. In addition, reactivation was  
33 significantly enhanced by the induction of DNA damage using a number of chemicals.  
34 Finally, we used recombinant viruses to show that VP22 is required for the induction of DNA  
35 damage *in vivo* and that this likely contributes to viral oncogenesis.

36

37 **IMPORTANCE**

38 Marek's Disease Virus is an oncogenic alphaherpesvirus that causes fatal T-cell lymphomas  
39 in chickens. MDV causes substantial losses in poultry industry and is also used as a small-  
40 animal model for virus-induced tumor formation. DNA damage is not only implicated in  
41 tumor development but also aids in the life cycle of several viruses, however its role in MDV  
42 replication, latency and reactivation remains elusive. Here, we demonstrated that MDV  
43 induces DNA lesions during lytic replication *in vitro* and *in vivo*. DNA damage was not  
44 observed in latently infected cells, however is reinitiated during reactivation. Reactivation  
45 was significantly enhanced by the induction of DNA damage. Recombinant viruses that  
46 lacked the ability to induced DNA damage were defective in the induction of tumors,  
47 suggesting that DNA damage might also contribute to cellular transformation processes  
48 leading to MDV-lymphomagenesis.

49

50 **Keywords:** Herpesvirus, Marek's disease virus, DNA damage, oncogenesis, viral replication,  
51 VP22

52

## 53 INTRODUCTION

54 Marek's disease (MD) is an oncogenic lymphoproliferative disease caused by the Marek's  
55 disease virus (MDV), also referred as to *Gallid herpesvirus 2*. MDV is a member of the  
56 *Alphaherpesvirinae* subfamily, mostly due to its genomic organization. However, MDV  
57 shows similarities with gammaherpesviruses considering its lymphotropic nature and  
58 oncogenic properties (1). Infection of susceptible chickens with very virulent MDV strains  
59 induces a rapid onset of tumors within 3-4 weeks and a high mortality. Intriguingly, MDV  
60 and the human herpesvirus 6 (HHV-6) integrate their genome into the telomeres of latently  
61 infected cells (2-5), allowing the long-life persistence of the virus in the host. Therefore,  
62 MDV is used to assess herpesvirus integration as well as virus-induced lymphomagenesis (6).  
63 The MDV life cycle is complex and can be broken down into four phases (7, 8): (i) an early  
64 cytolitic phase, corresponding to the replication of MDV in B- and T-lymphocytes during the  
65 first week of infection; (ii) the establishment of a latent infection in CD4+ T-lymphocytes  
66 between 7-10 days post-infection (dpi) during which MDV is thought to integrate its genome  
67 into host telomeres ; (iii) the reactivation of the virus from latently infected cells, which is  
68 accompanied by its late replication and continuous shedding of the virus from the feather  
69 follicle epithelium; and (iv) the tumorigenic phase characterized by transformation of CD4+  
70 T-lymphocytes and the development of T-cell lymphoma.  
71 Several viral oncogenes have been identified such as the latent oncoprotein Meq and the viral  
72 telomerase RNA subunit, vTR (9-15), however the exact mechanism leading to lymphoma  
73 development remains poorly understood. We recently demonstrated that during lytic  
74 replication MDV triggers cell proliferation and subsequently delays the cell cycle in S-phase  
75 (16). In addition, we showed that the tegument protein VP22 is able to induce the S-phase  
76 arrest in the absence of other viral proteins. This blockade is associated with a massive onset  
77 of double strand breaks (DSBs). The VP22 tegument protein is encoded by the UL49 viral

78 gene and is part of the MDV virion. VP22 is involved in cell-to-cell spread of MDV and is  
79 essential for MDV replication (17). Beyond its role in MDV replication, VP22 potentially  
80 contributes to the establishment of latency and/or transformation by its ability to interact with  
81 DNA/histones, to interfere with the cell cycle progression, and to mediate DNA damage.  
82 Moreover, it was shown that a recombinant MDV expressing a VP22 with a C-terminal GFP-  
83 tag is highly attenuated *in vivo*, suggesting that VP22 plays a role in MDV-induced  
84 tumorigenesis (18). In addition, we have previously observed that such a modification of the  
85 VP22 C-terminus abolishes its ability to modulate the cell cycle and to induce DNA damage  
86 upon overexpression of the protein in proliferating cells (16). Of note, the fusion of GFP to  
87 the N-terminus of VP22 did not affect these properties *in vitro* and only mildly attenuates the  
88 virus *in vivo* (16, 19).

89 Chromosomal aberrations and modulation of DNA damage response (DDR) are commonly  
90 encountered during viral infections and are important for the viral life cycle as reviewed  
91 previously (20-26). This has been particularly evidenced in herpesvirus infections for which  
92 the ATM (Ataxia Telangiectasia-mutated) and ATR (ATM and Rad3 related) DNA damage  
93 pathways proteins play a beneficial role for viral replication (27-31). Effectors of the DDR  
94 and DNA repair pathways also facilitate virus maintenance and the establishment of latency  
95 (31-33). Moreover, in the case of oncogenic viruses such as the Epstein Barr virus (EBV) and  
96 the Kaposi sarcoma-associated herpesvirus (KSHV), the deregulation of these pathways and  
97 the induction of DNA damage are of particular importance since genomic instability promotes  
98 the establishment of neoplastic processes (34-40). DNA damage has been previously observed  
99 in the blood of chickens diagnosed with MD infected with uncharacterized field viral strains  
100 (41), however it remained unclear if this damage occurs in lymphocytes and if this is also the  
101 case during early infection.

102 In the present study, we aimed to elucidate the kinetics of DNA damage in MDV infection to  
103 determine the role of DNA damage on the MDV life cycle. We demonstrated that DNA  
104 breaks accumulate in lytically infected cells *in vivo* and *in vitro*, but not in latently infected  
105 cells. We also showed that DNA damage and/or DDR are actively induced upon MDV lytic  
106 replication and reactivation from the latent stage. We demonstrated *in vivo* that VP22 is  
107 required for the induction of DNA damage using recombinant viruses. Also, we observed that  
108 a recombinant virus that lacked the ability to induced DNA damage was defective in the  
109 induction of tumors, suggesting that DNA damage induction might participate to the  
110 oncogenicity of MDV.

111

## 112 MATERIALS AND METHODS

### 113 Cells and viruses

114 Chicken embryo skin cells were prepared from 12 day-old specific pathogen-free (SPF) White  
115 Leghorn (LD1) embryos and maintained in culture as previously described (42). The MDCC-  
116 3867K cell line was derived from a renal lymphoma induced upon infection of chicken with  
117 the highly pathogenic recombinant vRB-1B 47EGFP virus encoding the UL47 gene fused to  
118 the enhanced green fluorescent protein (EGFP) (43). 3867K cells were cultured in RPMI 1640  
119 supplemented with 2 mM glutamine, 1% pyruvate, 1% non-essential amino acids, 1%  
120 glucose, 10% tryptose phosphate broth and 10% fetal bovine serum (FBS) and maintained at  
121 41 °C in a 5% CO<sub>2</sub> atmosphere. RECC-CU91 T-cells, a reticuloendotheliosis virus (REV)-  
122 transformed chicken T-cell line, were cultured in RPMI 1640 supplemented with 1%  
123 pyruvate, 1% non-essential amino acids, 10% fetal bovine serum (FBS) and  
124 penicillin/streptomycin, and maintained at 41°C in a 5% CO<sub>2</sub> atmosphere (44).

125 To visualized virus infected cells, EGFP was fused to the 5' end of the UL49 gene in the  
126 avirulent BAC20, resulting in recEGFPVP22 (45). Very virulent, spread competent vRB-1B

127 virus was reconstituted from the infectious bacterial artificial chromosome (BAC) of RB-1B  
128 as described previously (46). In addition, recombinant RB-1B were previously generated with  
129 EGFP fuses to the 5' and 3' end of VP22, termed vRB-1B EGFP22 and vRB-1B 22EGFP  
130 respectively (18, 19). All recombinant viruses were reconstituted, propagated and titrated as  
131 described previously (45).

132 Infections of RECC-CU91 T-cells were performed by co-cultivation with infected CESC  
133 (47). One million CESC were infected with  $3 \times 10^4$  PFU of RB-1B\_TK-GFP that expresses  
134 GFP under the control of the early HSV-1 TK promoter for 3-4 days in 6-well plates.  
135 Subsequently,  $10^6$  RECC-CU91 T-cells were added to the highly infected CESC monolayer  
136 for 16 hours at 41°C. RECC-CU91 cells were carefully removed at day 1, 2 and 3 post-  
137 infection for further analysis.

#### 138 **Pharmacological induction of DNA damages**

139 DNA damage was induced in cells by etoposide (ETP; Sigma-Aldrich), bleomycin  
140 (Calbiochem), hydroxyurea (HU; Sigma-Aldrich) and hydrogen peroxide ( $H_2O_2$ ; Sigma-  
141 Aldrich) treatments. At 6h post-infection, CESC infected with the recEGFPVP22 were  
142 treated by addition in the culture media of the pharmacological agents at appropriate  
143 concentrations (0.033, 0.066 or 0.132  $\mu$ M of ETP; 0.125 to 1  $\mu$ M of bleomycin; 10 to 75  $\mu$ M  
144 of HU and 12.5 to 100  $\mu$ M of  $H_2O_2$ ). ETP treated infected cells were analyzed at 24, 48, 72,  
145 and 96h post-infection and bleomycin, hydroxyurea and hydrogen peroxide treated cells at  
146 72h. RECC-CU91 cells were treated at the time of infection with 0.02  $\mu$ M or 0.1  $\mu$ M ETP for  
147 24, 48 and 72h pi. Treatments of 3867K cells were performed for 48h with 0.004 to 0.5  $\mu$ M of  
148 ETP; 1 to 25  $\mu$ M of bleomycin; 0.0625 to 1 mM of HU and 0.1 to 1 mM of  $H_2O_2$ . In all  
149 experiments, DMSO (for ETP) or  $H_2O$  (for bleomycin, HU and  $H_2O_2$ ) was used as negative  
150 control and added in the culture medium at a volume equivalent to the corresponding to the  
151 highest concentration of drug treatments.



## 152 **Animal experiments**

153 Two *in vivo* experiments were conducted in this study according to the guidelines and  
154 regulations as outlined that were approved by the local ethic committee “Comité d’Ethique  
155 pour l’Expérimentation Animale de Val de Loire” (CEEA VdL, protocol number 2012-09-3).  
156 In the first experiment (Fig. 4), 24 days-old SPF white leghorn chicks (B13/B13 haplotype)  
157 were infected intramuscularly (pectoral muscles) with 1,000 pfu of vRB-1B (n=13) or mock  
158 infected (n=10) and housed in isolation units. In the second experiment (Fig. 5), chickens  
159 were either infected with 1,500 pfu of vRB-1B (n=6), vRB-1B EGFP22 (n=12), vRB-1B  
160 22EGFP (n=13) or mock infected (n=10) as described above. Of note, in order to inoculate  
161 an equal amount of virus to chickens, vRB-1B EGFP22 and vRB-1B 22EGFP viral inoculum  
162 were exclusively constituted of EGFP+ positive sorted CESC (i.e. infected cells). Birds were  
163 evaluated daily for symptoms of MD. In the case of clinical evidence of MD, the chickens  
164 were euthanized and examined postmortem for the presence of gross MD lesions. At the end  
165 of the experiments (35 dpi in experiment #1 and 49 dpi in experiment #2), all surviving birds  
166 were euthanized and necropsied. To assess the DNA damage in peripheral blood mononuclear  
167 cells and to follow the viral load, blood was collected on 3% sodium citrate from all birds at  
168 0, 7, 14, 21, 28 and 35 dpi for experiment #1 and 0, 7, 14, 21, 28, 35 42 and 49 dpi for  
169 experiment #2. PBMCs were isolated from 1 ml of whole blood using lymphocytes-separation  
170 medium LSM (Eurobio, France) as previously described (19).

## 171 **DNA extraction and real-time quantitative PCR (qPCR)**

172 To quantify the viral load, DNAs were extracted from 30 µl whole blood (animal experiment  
173 #1) or from  $2 \times 10^6$  isolated cells (PBMCs in the animal experiment #2, CESC and RECC-  
174 CU91 cells), using the QIAamp DNA mini kit according to the manufacturer’s instructions  
175 (Qiagen). MDV genome copies were quantified by qPCR as previously described (19, 48).

176 The MDV genome was detected using primers and probes against the ICP4 gene and was  
177 normalized to  $10^6$  copies of cellular genome quantified by the detection of the iNOS gene.

#### 178 **RNA extraction and quantitative Reverse Transcription-PCR (qRT-PCR)**

179 RNAs were extracted from  $10^6$  non-infected and recEGFPVP22 infected CESC's, PBMCs  
180 isolated from vRB-1B infected chickens and 3867K cells, using the RNeasy Mini kit  
181 following the manufacturer's instructions (Qiagen). RNAs were treated with RNase-free  
182 RQ1 DNase (Promega, France) and the RNA concentration was measured with a NanoDrop  
183 spectrophotometer. One  $\mu$ g of total RNA was reverse transcribed using 100  $\mu$ g/mL oligo(dT)  
184 primers (Promega) and M-MLV reverse transcriptase (Promega). The expression of the genes  
185 of interest was then assessed by qRT-PCR using the Supermix SYBR green (Bio-Rad) as  
186 previously described (16). The sequence of the specific primer pairs used for the amplification  
187 of the viral and cellular genes are depicted in Table 1. Expression of the chicken  
188 glyceraldehyde phosphate dehydrogenase (GAPDH) was used for the normalization and the  
189 relative changes in gene expression were determined by the  $2(-\Delta\Delta CT)$  method.

#### 190 **Cell sorting and flow cytometry analysis**

191 Sorting of CESC's infected with recombinant viruses expressing fluorescent VP22 proteins  
192 were performed at 4 dpi. The 3867K cells exhibiting MDV lytic replication were sorted on the  
193 basis of the expression of the UL47 protein tagged with EGFP. Mock-infected CESC's  
194 (negative control) were also sorted to avoid experimental bias linked to sorting. Damaged  
195 cells and debris were eliminated on the basis of morphological criteria. EGFP positive and  
196 negative cells were sorted using a MoFlo<sup>®</sup> high-speed cell sorter (Beckman Coulter, Fort  
197 Collins, CO, USA).

198 The percentage of lytically infected 3867K and RECC-CU91 T cells was determined by  
199 cytometry on the basis of the expression of the GFP (associated to the expression of UL47  
200 and TK-promoter, respectively). Cell viability was estimated using the fixable viability dye

201 eFluor® 780 (eBioscience) at dilution of 1:1000. Staining was performed for 15 minutes on  
202 ice in the dark. Cells were washed twice in PBS before being fixed with paraformaldehyde  
203 (PAF) 1%. Cell viability was analyzed with a 780/40 nm band-pass filter.

#### 204 **Alkaline comet assay**

205 Alkaline comet assays were performed from  $2 \times 10^5$  cells as previously described (16, 49).  
206 Two slides for comet assays were prepared for each condition. Comets were observed using  
207 the Axiovert 200 M inverted epifluorescence microscope (Zeiss) and images were taken with  
208 an Axiocam MRm camera (Zeiss). A minimum of 50 comets was analyzed for each replicate  
209 using the CometScore software version 1.5 (TriTek). The olive tail moment parameter (OTM)  
210 was calculated on the basis of the tail length and the relative proportion of DNA contained in  
211 the tail. Results are presented as the mean ( $\pm$ SD) of the OTM calculated for each condition or  
212 as a distribution of the comets with respect to their respective OTM value (i.e. the percentage  
213 of cells presenting a defined OTM).

#### 214 **Reactive oxygen species (ROS) assay**

215 ROS production was assayed from supernatant (80  $\mu$ l) of mock- and recEGFPVP22-infected  
216 CESC's at 24h, 48h, 72h and 96h pi using the ROS-Glo™  $H_2O_2$  assay following  
217 manufacturer's instructions (Promega). Luminescence quantification was performed using a  
218 Glomax® Multidetector system luminometer (Promega). Results were recorded as relative  
219 luminescent units (RLU). Assays were done in triplicates at each time point. Results obtained  
220 from infected-cells were normalized to that of mock-infected conditions and expressed as  
221 means ( $\pm$ SD).

#### 222 **Nitric oxide (NO) assay**

223 NO produced from infected and mock-infected CESC's was measured at 24, 48, 72 and 96 hpi  
224 by detecting the accumulation of nitrite ( $NO_2^-$ ) in the culture media using the Griess reaction  
225 (50). Fifty microliters of cell culture supernatant were collected at each time point in a 96-

well plate (in triplicates) and incubated for 10 min in the dark with 100  $\mu$ l of Griess reagent (mixture (1:1) of 1% sulfanilamide (Sigma-Aldrich) in 1.2 N hydrochloric acid and 0.3% N-1-naphthylethylenediamine dihydrochloride (Sigma-Aldrich)). Absorbance was then measured at 540 nm. Nitrite concentrations were calculated with reference to a calibration curve established using standard solutions ranging from 0 to 200  $\mu$ M of sodium nitrite (Sigma-Aldrich) diluted in culture medium. A positive control consisting of supernatant of *E.coli* infected cells was included in the assay as well as cell-free media as negative control.

### Fluorescence Microscopy

CESCs were grown on glass coverslips and infected with recEGFPVP22. At 4 days pi, infected and non-infected cells were fixed with 4% PFA for 20 min at room temperature (RT) and permeabilized with 0.5% Triton X-100 for 5 min at RT. After blocking with PBS, 0.1% Triton X-100 and 2% Bovine Serum Albumin (BSA), cells were incubated with mouse monoclonal IgG directed against phospho-histone H2AX (Ser139) (Millipore; clone JBW301) at a dilution of 1:500. Goat anti-mouse IgG Alexa-Fluor 594 secondary antibody (Invitrogen) was used at 1:2000. Nuclei were counterstained with Hoechst 33342 (Invitrogen). EGFP fluorescence was directly observed from cells expressing the viral EGFP-tagged VP22 protein. Cells were observed under an Axiovert 200 M inverted epifluorescence microscope equipped with a 40 $\times$  PlanNeofluar oil/Dic objective or a 63 $\times$  PlanApochromat oil/DIC and the Apotome imaging system (Zeiss). Images were captured with a CCD AxioCam MRm camera (Zeiss) by using the Axiovision software.

### MDV plaque size measurement assay

At 48 hpi, CESC monolayers infected with the recEGFPVP22 virus and treated with ETP were fixed with 4% PFA. Fluorescence emitted from the viral EGFP-tagged VP22 protein was detected using Axiovert 200 M inverted epifluorescence microscope equipped with a 5 $\times$  Fluor objective. Viral plaques were measured and analyzed as previously described (45).

## 251 **Statistical analysis**

252 All graphs and statistics were performed using the GraphPad Prism software version 5.02  
253 (San Diego, USA). Data are presented as means and standard deviations ( $\pm$ SD) or medians.  
254 The one-way ANOVA test was used to compare differences in multiple groups and the Mann-  
255 Whitney (two-tailed) was used to compare nonparametric variables between two groups.  
256 Significant differences were determined using Student's *t*-test. *P* values <0.05 were  
257 considered statistically significant as indicated in the figure legends.

## 258 **RESULTS**

### 259 **MDV replication induces double strand breaks in the host genome**

260 Until now, it remained unknown if MDV induces DNA damage during virus replication.  
261 Therefore, we infected CESC's with a recombinant virus containing EGFP fused to the N-  
262 terminus of VP22 (recEGFPVP22). GFP-positive MDV infected and GFP-negative cells were  
263 sorted by flow cytometry 96 hpi and DNA damage was assessed by alkaline comet assay.  
264 MDV infection increased the rate of DNA damage by 8.5-fold and 6-fold compared to GFP-  
265 negative and mock-infected cells, respectively (Fig. 1A). In addition, up to 30% of the  
266 infected cells had an OTM score greater than 10, indicative of highly damaged DNA (Fig.  
267 1B). To identify the nature of the DNA damage in infected cells, we monitored the expression  
268 and localization of  $\gamma$ -H2AX, a marker classically used to detect double strand breaks (DSBs).  
269 Immunofluorescence analyses revealed a significant increase in intensity of  $\gamma$ -H2AX and a  
270 typical localization of the protein as foci in the nucleus of CESC's infected with the  
271 recEGFPVP22 virus (Fig. 1C) indicative of the presence of DSBs.

### 272 **Induction of DNA damage enhances MDV replication**

273 To determine if the induction of DNA damage and/or the subsequent DDR is beneficial for  
274 MDV replication, we infected CESC's with recEGFPVP22 in the presence or absence of  
275 potent DSB inducer etoposide (ETP) (51) and monitored MDV replication by qPCR (Fig. 2A

276 and B). MDV replication was significantly increased in the presence of ETP at 96 hpi  
277 compared to DMSO treated control cells, and the greatest increase was observed for the  
278 highest ETP concentration (Fig. 2A and B). To confirm that the observed effect is indeed due  
279 to the induction of DNA damage, we also tested a number of pharmacological agents known  
280 to generate single-strand and DSB, replicative stress and/or oxidative stress (bleomycin,  
281 hydroxyurea (HU) and H<sub>2</sub>O<sub>2</sub>). As for ETP treatment, CESC's were infected with  
282 recEGFPVP22 and treated with these drugs at different concentrations and MDV copy  
283 number was assayed at by qPCR (Table 2). The overall effect of the DNA damaging agents  
284 tested was more moderate than ETP on MDV infected-cells, although all reagents tended to  
285 increase slightly viral replication, underlining that DNA damage enhances MDV replication.  
286 In addition, we could demonstrate that ETP increases the percentage of viable GFP-VP22  
287 expressing cells in a dose dependent manner when compared to DMSO-treated control cells  
288 (Fig. 2C). This increase in infected cells was significant for the highest ETP concentrations.  
289 Furthermore, MDV plaques were also significantly larger upon induction of DNA damage  
290 (Fig. 2D), indicating that the virus spread more efficiently to surrounding cells. Beyond that,  
291 we also assessed the effect of ETP treatment on MDV replication in T cells, the natural target  
292 of MDV infection. RECC-CU91 T cell were infected with RB-1B\_TK-GFP in presence of  
293 ETP and MDV copy number was monitored by qPCR (Fig. 2E). The impact of ETP treatment  
294 on MDV replication in T-cells is more mitigated than in CESC's, however MDV genome  
295 copies slightly increase from one day pi when cells were treated with the highest ETP  
296 concentration.  
297 Taken together, our data demonstrate that additional induction of DNA damage and/or the  
298 subsequent DDRs are beneficial for MDV replication.

299

300

301 **MDV replication induces reactive oxygen species (ROS) and nitric oxide (NO)**  
302 **production in CESC**

303 Next we assessed if MDV induced DNA damage is mediated by oxidative stress, a common  
304 cause of DSBs (52). We first monitored the level of ROS by measuring the production of  
305 hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) in the supernatant of MDV or mock-infected cells (Fig. 3A). A  
306 significant accumulation of H<sub>2</sub>O<sub>2</sub> was detected in the supernatant of infected cells from 48 to  
307 96 hpi. Besides ROS, reactive nitrogen species such as nitric oxide (NO) also plays a role in  
308 metabolic stress and oxidative DNA damage in cells (53). We measured NO production in the  
309 supernatant of infected and mock-infected cells and observed a significant increase of NO at  
310 72 hpi (Fig. 3B). NO can be generated by the inducible nitric oxide synthases (iNOS) that is  
311 generally activated upon immune response. Intriguingly, NO production coincided with an  
312 increase expression of iNOS at 72 hpi (Fig. 3C). Our data suggest that MDV infection is  
313 associated with an increased level of reactive oxygen and nitrogen species that could  
314 contribute to the DNA damage in infected cells.

315 **DNA damage induction in chicken peripheral blood mononuclear cells upon MDV**  
316 **infection**

317 To determine if MDV induces DNA lesions *in vivo*, we infected chickens with the very  
318 virulent MDV strain vRB-1B. Blood was collected from all animals at various time points.  
319 Viral load was assessed by qPCR on whole blood and DNA damage was determined using the  
320 alkaline comet assay on isolated peripheral blood mononuclear cells (PBMCs). In addition,  
321 the establishment of viral latency was followed by analyzing the mRNA expression of Meq  
322 by qRT -PCR in non-infected and vRB-1B infected PBMCs. Intriguingly, DNA damage was  
323 significantly increased (about 3-fold higher) in PBMCs of infected chickens during the lytic  
324 phase of the MDV life cycle at 7 dpi (Fig. 4A). In contrast, no increase in DNA lesions was  
325 observed in the latent phase of infection after 14 dpi. The increased in DNA damage was



326 associated with a 100-fold increase in viral load in the blood during the lytic phase of  
327 infection (Fig. 4B). After day 14, high levels of the major oncogene Meq were observed by  
328 qRT-PCR, corresponding to latently infected or MDV transformed cells (Fig. 4C) and are in  
329 agreement with previous reports on the establishment of latency (54, 55). Thus, our data  
330 shows that MDV early lytic infection is associated with transient DNA damage in PBMCs,  
331 while no DNA damage was detected at later stages of infection.

332 **VP22 contributes to the DNA damage upon MDV infection *in vivo*.**

333 We previously demonstrated that overexpression of VP22 arrests the cell cycle and induces  
334 DNA damage *in vitro* (16). In addition, we showed that MDV harboring EGFP fused to the C-  
335 terminus of VP22 (vRB-1B 22EGFP) is severely attenuated, while fusion to the N-terminus of  
336 VP22 (vRB-1B EGFP22) induces only a mild decrease in oncogenicity (18, 19), suggesting  
337 that the C-terminal fusion affects VP22 function. Based on this observation, we assess the  
338 induction of DNA damage mediated by these recombinant viruses *in vivo*. We infected SPF  
339 chickens with either wild-type vRB-1B, vRB-1B 22EGFP or vRB-1B EGFP22 and monitored  
340 DNA damage, virus replication and tumor development. Intriguingly, DNA damage at day 7  
341 was only observed in PBMCs of birds infected with wild-type vRB-1B and vRB-1B EGFP22,  
342 suggesting that the fusion of GFP to the N terminus of VP22 does not affect DNA damage  
343 induction (Fig. 5A). In contrast, levels of DNA damage in PBMCs of vRB-1B 22EGFP  
344 infected animal was comparable to mock infected chickens, indicating that fusion of GFP to  
345 the C-terminus of VP22 disrupts its ability to mediate DNA lesions. To ensure that this effect  
346 was not just due to a reduced virus replication, we monitored virus load in PBMCs by qPCR  
347 and could demonstrate that virus replication was only mildly reduced at day 7. In contrast, a  
348 significant decrease was observed at days 14 and 28 pi between vRB-1B 22EGFP and the  
349 parental virus (Fig. 5B). Since DNA damage also plays an important role in cancer  
350 development, we also monitored tumor incidence in the infected chickens. As observed



351 previously, tumor formation was severely impaired for vRB-1B 22EGFP (31 %) that cannot  
352 induce DNA damage, while tumors were efficiently induced by wild-type vRB-1B (100 %)  
353 and vRB-1B EGFP22 (66%). Our data shows that DNA damages is dependent on a functional  
354 VP22 and that tumor formation is severely impaired for a virus that cannot induce DNA  
355 damage.

### 356 **MDV reactivation is accompanied and enhanced by DNA damage**

357 Next, we set to determine if DNA damage is induced upon MDV reactivation. We  
358 used a lymphoblastoid cell line that expresses GFP fused to the tegument protein UL47 upon  
359 reactivation (3867K) as described previously (43). We sorted EGFP positive and negative  
360 cells and assessed DNA damage by comet assays. DNA damage was significantly increased  
361 in reactivating (GFP+) cells compared to the latent, GFP negative cells (Fig. 6A), indicating  
362 that MDV reactivation in T cells is associated with DNA damage. An increased proportion of  
363 reactivating cells also showed high levels of DNA damage (8%, OTM>10), while only  
364 minimal damage is seen in latently infected cells (Fig. 6B). Next, we evaluated if DNA  
365 damage can also increase reactivation. We induced DNA damage in 3867K with increasing  
366 concentration of ETP for 48 hours. Both ICP4 expression and the number of GFP expressing  
367 cells was significantly increased in a dose dependent manner (Fig. 6C and D). To confirm that  
368 effect of DNA damage on MDV reactivation, we treated 3867K cells with bleomycin, HU and  
369 H<sub>2</sub>O<sub>2</sub>. MDV reactivation was significantly increased in a dose dependent manner for all three  
370 DNA damage inducing drugs (Fig. 6E). Taken together, our data demonstrate that DNA  
371 damage is induced upon MDV reactivation and that induction of DNA damages seem to be  
372 favorable for MDV reactivation.

### 373 **DISCUSSION**

374 The hallmark of the present study is the observation of an onset of DNA lesions in cells  
375 sustaining MDV replication *in vitro* and *in vivo*. This was initially shown *in vitro* in MDV-

376 infected CESCes in which we detected DNA DSBs at 96 hpi. *In vivo*, we demonstrated that  
377 MDV early cytolitic replication is associated with an increase in DNA damages in PBMCs of  
378 infected chickens early after infection (7 dpi). Moreover, we showed *in vitro* that  
379 lymphoblastoid cells (3867K) undergoing MDV replication induced from the spontaneous  
380 reactivation of the virus are also affected by DNA damage. Of note, DNA damage during  
381 MDV reactivation in the PBMCs of birds infected with the highly virulent RB-1B was not  
382 statistically significant different from that of the mock-infected birds at 21 dpi, the time point  
383 at which a peak of viral reactivation is expected. This might be due to the fact that only a  
384 small number of CD4+ T cells reactivate in the blood and the low sensitivity of the comet  
385 assay.

386 Intriguingly, DNA lesions were detected at 7 dpi in the PBMCs of chickens infected with both  
387 vRB-1B or vRB-1B EGFP22 virus, but not with the attenuated vRB-1B 22EGFP virus, even  
388 though all 3 viruses showed similar robust viral DNA replication as was assessed by qPCR  
389 results. This observation may indicate that MDV replication is not sufficient to induce DNA  
390 breaks. However, at 14 and 28 dpi the attenuated vRB-1B 22EGFP virus displayed a lower  
391 replication rate compared to the wild-type vRB-1B virus. We could assume that this growth  
392 defects might be associated with the low rate of DNA lesions occurring during the early  
393 replication of the virus (at 7 dpi), and thus that DNA damage might be favorable for MDV  
394 replication. These observations also confirmed that VP22 is a major viral determinant  
395 associated to DNA damages *in vivo*. The VP22 tegument protein is abundantly expressed  
396 during viral lytic infection and essential for MDV replication (17, 42). In a previous study, we  
397 also reported that the overexpression of VP22 leads to DSB induction in proliferating cells,  
398 and that this activity of VP22 depends on an unmodified C-terminal extremity (16). Herein,  
399 we show *in vivo*, in an infectious context, that VP22 is involved in the induction of DNA  
400 lesions observed during MDV early cytolitic infection, and that the modification of the C-

401 terminal extremity of the protein subverted the ability of MDV to trigger DNA damage in  
402 PBMCs. It should also be noted that the level of DNA lesions detected at 7 dpi in PBMCs  
403 from infected birds is somewhat surprising given the low number of circulating infected cells  
404 and seems to indicate that non-infected cells might also be subjected to DNA damage. The  
405 lesions observed in the non-infected population could be attributed to the inflammatory  
406 immune response and/or paracrine signaling molecules emitted from infected cells and  
407 responsible of a bystander effect (56-58). Also, despite conflicting reports about the  
408 intercellular trafficking property of the VP22 protein, we cannot exclude that VP22 could  
409 spread to non-infected surrounding cells and contribute to the generation of DNA lesions in  
410 these cells (59-61). The mechanism by which VP22 is involved in the onset of DNA lesions is  
411 still unclear. MDV VP22 could have a direct genotoxic activity on DNA since VP22 can  
412 interact with DNA and histones (16, 42), or could activate cellular metabolism pathways  
413 leading to DNA damage. In support to the latter hypothesis, we showed that MDV infection  
414 triggers oxidative stress in CESC. We detected an increase of hydrogen peroxide production  
415 from 48 hpi in CESC infected with MDV. In addition, a higher level of nitrites associated to  
416 an increase of iNOS mRNA expression was detected at 72 hpi in the supernatant of MDV-  
417 infected CESC compared to mock-infected cells. Previous studies reported that MDV  
418 infection influences the production of NO (41, 48). A correlation was notably established  
419 between the virulence of MDV strains and its ability to induce NO, with the most virulent  
420 strains inducing the highest level of NO (48). It is believed that NO plays a role in MDV  
421 pathogenesis through its involvement in the immune suppression observed early after  
422 infection (48). Nevertheless, the role of NO on MDV replication is still not clearly elucidated.  
423 NO production was identified as an anti-viral process by inhibiting MDV replication *in vitro*  
424 and *in vivo* (62, 63). However, Jarosinski *et al.* demonstrated that despite a high NO response,  
425 chickens infected with very virulent MDV strains showed an enhanced cytolytic infection

(48). Oxidative stress is a major generator of DNA breaks including DSBs (64). We could thus hypothesize that oxidative stress generated during MDV replication could participate in the generation of DNA lesions, which in turn would facilitate MDV replication and consequently potentiate the virulence of MDV. We have indeed demonstrated that DNA damage seems to favor the replication of the virus, since we have shown that DNA damaging pharmacological agents can promote MDV replication and enhance MDV reactivation from latent infection. Of note, the impact on MDV replication seemed to depend on the drug used and thus probably on the nature of the damages generated and/or the damage response (DDR) associated. Also, the response to different treatments might vary between cells according to their lineage (lymphoid, fibroblastic) and their proliferative potential (primary versus cell lines). Hence, ETP treatment (inducing mainly DSBs) resulted in an increase of MDV replication in CESC, while bleomycin, hydroxyurea and H<sub>2</sub>O<sub>2</sub> treatments had a weaker effect in CESC. One explanation might be the low proliferative rate of CESC that may counteract the activity of drugs inducing damage during S phase. ETP had also mild effect on MDV replication in CU-91 T- cell line. Also, CU-91 were initially transformed with REV, we could thus hypothesize that the presence of a replicative retrovirus might disturb the DNA damage responses in these cells and/or have an impact on MDV replication. On the other hand, all treatments induced a significant increase of MDV reactivation in a lymphoid cell line transformed by MDV. We cannot currently specify whether DNA damages only or the induction of the DDR associated with the onset of damage promotes MDV replication. As previously demonstrated for a number of viruses and especially herpesviruses, the DNA damage response (DDR) plays a major role in viral replication (for review see (20, 22-24, 26, 65)). Unfortunately, we were not able to characterize more precisely the DDR pathways induced during MDV infection in the present study due to a lack of specific tools cross-reacting with chicken proteins. Nevertheless, we hypothesized that MDV infection induces

the activation of a DDR as it was demonstrated for other herpesviruses. We identified at least two processes that could contribute to the DDR pathways activation: (i) the generation of DNA lesions in cellular DNA triggered upon MDV replication, and (ii) the increase of oxidative stress in MDV-infected CECs. Elevated levels of ROS are known to activate DDR pathways, as demonstrated notably upon EBV infection in which the latent protein EBNA1 promotes ROS accumulation and consequently ATM-dependent DDR activation (34). Moreover, our previous study demonstrated that MDV induces an S-phase arrest in fibroblasts (16). This constitutive S-phase induction may generate a favorable environment for viral replication but could also lead to replicative stress, a potent mechanism responsible of DDR induction. Although we currently cannot determine the DDR pathways activated by MDV, we can speculate that ATM signaling may be induced in response to the DSBs and to the oxidative stress generated during MDV infection (66, 67). Of note, ATM pathway activation seems to be a common characteristics of herpesviruses infections (as previously reported notably for the human herpesvirus type-1 (HSV-1), the cytomegalovirus (CMV, EBV and KSHV), and in most cases ATM has been demonstrated to be beneficial for viral replication (28, 68-70).

Finally, a major point of interest of the present study is the potential involvement of the onset of DNA lesions in MDV-induced lymphomagenesis. Many reports have shown that DNA damage and the DDR can contribute to genomic instability in cells and in turn to the development of tumors. Moreover, DSBs are among the most deleterious lesions occurring in cells and if not repaired, accumulation of DSBs could promote cell-death or the loss of genome integrity possibly leading to carcinogenesis (71). Several studies demonstrated the interplay between oncogenic viruses and DNA damage/DDR signaling and its crucial implication in virus mediated-tumorigenesis (for review see (35, 39, 40)). Our data support these findings since we observed a greater rate of DNA damage in PBMCs from chickens

476 infected with virulent MDV viruses (vRB-1B and vRB-1B EGFP22) and to a significantly  
477 lesser extent in PBMCs of birds infected with an attenuated recombinant virus (vRB-1B  
478 22EGFP). The low oncogenicity of the vRB-1B 22EGFP virus might well be associated with  
479 its diminished replication capacity (as observed at day 14 pi). However, in the light of our  
480 results, one can also speculate that the viral phenotype is due to the absence of an early onset  
481 of DNA lesions in infected leukocytes that otherwise might contribute to MDV induced  
482 tumorigenesis. One hypothesis would be that the enhanced MDV replication upon, could  
483 result in an increased number of latently infected cells from which transformed T cells  
484 originate. DNA damage could also play a direct role in the establishment of viral latency and  
485 more precisely in the integration process of the viral genome. We indeed cannot exclude that  
486 the DNA lesions observed at an early time point of MDV infection could arise before or  
487 concomitantly to MDV latent infection in CD4<sup>+</sup> T-lymphocytes and thus could facilitate  
488 MDV genome integration either directly or indirectly by triggering DDR and DNA repair  
489 pathways, especially homologous recombination, as it was previously suggested for the  
490 hepatitis B virus, human Papillomaviruses, Merkel Cell Polyomavirus and EBV (2, 3, 72, 73).  
491 However, one should not underestimate the impact of a potential genomic instability  
492 originating from DNA damage generated during MDV replication. It is indeed conceivable  
493 that, in a particular sequence of events including cell cycle deregulation, reprogramming of  
494 gene expression by viral oncogenes (notably Meq) and telomerase activation, the  
495 accumulation of DNA lesions upon MDV infection may also contribute to the transformation  
496 process ultimately leading to MD lymphoma formation.

#### 497 **ACKNOWLEDGEMENTS**

498 We thank F. Paillard for editing the manuscript, D. Pasdeloup and S. Trapp for their  
499 constructive comments and corrections on the manuscript, as well as C. Berthault and K.  
500 Courvoisier for their technical help.



501

## 502 REFERENCES

- 503 1. **Jha HC, Banerjee S, Robertson ES.** 2016. The Role of Gammaherpesviruses in Cancer  
504 Pathogenesis. *Pathogens* **5**.
- 505 2. **Delecluse HJ, Hammerschmidt W.** 1993. Status of Marek's disease virus in established  
506 lymphoma cell lines: herpesvirus integration is common. *J Virol* **67**:82-92.
- 507 3. **Kaufer BB, Jarosinski KW, Osterrieder N.** 2011. Herpesvirus telomeric repeats facilitate  
508 genomic integration into host telomeres and mobilization of viral DNA during reactivation. *J*  
509 *Exp Med* **208**:605-615.
- 510 4. **Arbuckle JH, Medveczky MM, Luka J, Hadley SH, Luegmayer A, Ablashi D, Lund TC, Tolar J,**  
511 **De Meirleir K, Montoya JG, Komaroff AL, Ambros PF, Medveczky PG.** 2010. The latent  
512 human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes  
513 in vivo and in vitro. *Proceedings of the National Academy of Sciences of the United States of*  
514 *America* **107**:5563-5568.
- 515 5. **Wallaschek N, Sanyal A, Pirzer F, Gravel A, Mori Y, Flamand L, Kaufer BB.** 2016. The  
516 Telomeric Repeats of Human Herpesvirus 6A (HHV-6A) Are Required for Efficient Virus  
517 Integration. *PLoS Pathog* **12**:e1005666.
- 518 6. **Osterrieder N, Kamil JP, Schumacher D, Tischer BK, Trapp S.** 2006. Marek's disease virus:  
519 from miasma to model. *Nat Rev Microbiol* **4**:283-294.
- 520 7. **Calnek BW.** 2001. Pathogenesis of Marek's disease virus infection. *Curr Top Microbiol*  
521 *Immunol* **255**:25-55.
- 522 8. **McPherson MC, Delany ME.** 2016. Virus and host genomic, molecular, and cellular  
523 interactions during Marek's disease pathogenesis and oncogenesis. *Poult Sci* **95**:412-429.
- 524 9. **Burnside J, Bernberg E, Anderson A, Lu C, Meyers BC, Green PJ, Jain N, Isaacs G, Morgan**  
525 **RW.** 2006. Marek's disease virus encodes MicroRNAs that map to meq and the latency-  
526 associated transcript. *J Virol* **80**:8778-8786.
- 527 10. **Engel AT, Selvaraj RK, Kamil JP, Osterrieder N, Kaufer BB.** 2012. Marek's disease viral  
528 interleukin-8 promotes lymphoma formation through targeted recruitment of B cells and  
529 CD4+ CD25+ T cells. *J Virol* **86**:8536-8545.
- 530 11. **Nair V.** 2013. Latency and tumorigenesis in Marek's disease. *Avian Dis* **57**:360-365.
- 531 12. **Trapp S, Parcells MS, Kamil JP, Schumacher D, Tischer BK, Kumar PM, Nair VK, Osterrieder**  
532 **N.** 2006. A virus-encoded telomerase RNA promotes malignant T cell lymphomagenesis. *J Exp*  
533 *Med* **203**:1307-1317.
- 534 13. **Kung HJ, Xia L, Brunovskis P, Li D, Liu JL, Lee LF.** 2001. Meq: an MDV-specific bZIP  
535 transactivator with transforming properties. *Curr Top Microbiol Immunol* **255**:245-260.
- 536 14. **Lupiani B, Lee LF, Cui X, Gimeno I, Anderson A, Morgan RW, Silva RF, Witter RL, Kung HJ,**  
537 **Reddy SM.** 2004. Marek's disease virus-encoded Meq gene is involved in transformation of  
538 lymphocytes but is dispensable for replication. *Proc Natl Acad Sci U S A* **101**:11815-11820.
- 539 15. **Gimeno IM, Witter RL, Hunt HD, Reddy SM, Lee LF, Silva RF.** 2005. The pp38 gene of  
540 Marek's disease virus (MDV) is necessary for cytolytic infection of B cells and maintenance of  
541 the transformed state but not for cytolytic infection of the feather follicle epithelium and  
542 horizontal spread of MDV. *J Virol* **79**:4545-4549.
- 543 16. **Trapp-Fragnet L, Bencherit D, Chabanne-Vautherot D, Le Vern Y, Remy S, Boutet-Robinet E,**  
544 **Mirey G, Vautherot JF, Denesvre C.** 2014. Cell cycle modulation by Marek's disease virus: the  
545 tegument protein VP22 triggers S-phase arrest and DNA damage in proliferating cells. *PLoS*  
546 *One* **9**:e100004.
- 547 17. **Dorange F, Tischer BK, Vautherot JF, Osterrieder N.** 2002. Characterization of Marek's  
548 disease virus serotype 1 (MDV-1) deletion mutants that lack UL46 to UL49 genes: MDV-1  
549 UL49, encoding VP22, is indispensable for virus growth. *J Virol* **76**:1959-1970.

- 550 18. **Jarosinski KW, Arndt S, Kaufer BB, Osterrieder N.** 2011. Fluorescently tagged pUL47 of  
551 Marek's disease virus reveals differential tissue expression of the tegument protein in vivo. *J*  
552 *Virol* **86**:2428-2436.
- 553 19. **Remy S, Blondeau C, Le Vern Y, Lemesle M, Vautherot JF, Denesvre C.** 2013. Fluorescent  
554 tagging of VP22 in N-terminus reveals that VP22 favors Marek's disease virus (MDV)  
555 virulence in chickens and allows morphogenesis study in MD tumor cells. *Vet Res* **44**:125.
- 556 20. **Smith S, Weller SK.** 2015. HSV-I and the cellular DNA damage response. *Future Virol* **10**:383-  
557 397.
- 558 21. **Fortunato EA, Spector DH.** 2003. Viral induction of site-specific chromosome damage. *Rev*  
559 *Med Virol* **13**:21-37.
- 560 22. **Lilley CE, Schwartz RA, Weitzman MD.** 2007. Using or abusing: viruses and the cellular DNA  
561 damage response. *Trends Microbiol* **15**:119-126.
- 562 23. **Sinclair A, Yarranton S, Schelcher C.** 2006. DNA-damage response pathways triggered by  
563 viral replication. *Expert Rev Mol Med* **8**:1-11.
- 564 24. **Turnell AS, Grand RJ.** 2012. DNA viruses and the cellular DNA-damage response. *J Gen Virol*  
565 **93**:2076-2097.
- 566 25. **Weitzman MD, Carson CT, Schwartz RA, Lilley CE.** 2004. Interactions of viruses with the  
567 cellular DNA repair machinery. *DNA Repair (Amst)* **3**:1165-1173.
- 568 26. **Xiaofei E, Kowalik TF.** 2014. The DNA damage response induced by infection with human  
569 cytomegalovirus and other viruses. *Viruses* **6**:2155-2185.
- 570 27. **Hau PM, Deng W, Jia L, Yang J, Tsurumi T, Chiang AK, Huen MS, Tsao SW.** 2015. Role of ATM  
571 in the Formation of the Replication Compartment during Lytic Replication of Epstein-Barr  
572 Virus in Nasopharyngeal Epithelial Cells. *J Virol* **89**:652-668.
- 573 28. **Hollingworth R, Skalka GL, Stewart GS, Hislop AD, Blackbourn DJ, Grand RJ.** 2015. Activation  
574 of DNA Damage Response Pathways during Lytic Replication of KSHV. *Viruses* **7**:2908-2927.
- 575 29. **Mohni KN, Dee AR, Smith S, Schumacher AJ, Weller SK.** 2013. Efficient herpes simplex virus  
576 1 replication requires cellular ATR pathway proteins. *J Virol* **87**:531-542.
- 577 30. **Mounce BC, Tsan FC, Droit L, Kohler S, Reitsma JM, Cirillo LA, Tarakanova VL.** 2011.  
578 Gammaherpesvirus gene expression and DNA synthesis are facilitated by viral protein kinase  
579 and histone variant H2AX. *Virology* **420**:73-81.
- 580 31. **Lilley CE, Carson CT, Muotri AR, Gage FH, Weitzman MD.** 2005. DNA repair proteins affect  
581 the lifecycle of herpes simplex virus 1. *Proc Natl Acad Sci U S A* **102**:5844-5849.
- 582 32. **Jha HC, Upadhyay SK, M AJP, Lu J, Cai Q, Saha A, Robertson ES.** 2013. H2AX phosphorylation  
583 is important for LANA-mediated Kaposi's sarcoma-associated herpesvirus episome  
584 persistence. *J Virol* **87**:5255-5269.
- 585 33. **Tarakanova VL, Stanitsa E, Leonardo SM, Bigley TM, Gauld SB.** 2010. Conserved  
586 gammaherpesvirus kinase and histone variant H2AX facilitate gammaherpesvirus latency in  
587 vivo. *Virology* **405**:50-61.
- 588 34. **Gruhne B, Sompallae R, Masucci MG.** 2009. Three Epstein-Barr virus latency proteins  
589 independently promote genomic instability by inducing DNA damage, inhibiting DNA repair  
590 and inactivating cell cycle checkpoints. *Oncogene* **28**:3997-4008.
- 591 35. **Hollingworth R, Grand RJ.** 2015. Modulation of DNA damage and repair pathways by human  
592 tumour viruses. *Viruses* **7**:2542-2591.
- 593 36. **Koopal S, Furuholm JH, Jarviluoma A, Jaamaa S, Pyakurel P, Pussinen C, Wirzenius M,**  
594 **Biberfeld P, Alitalo K, Laiho M, Ojala PM.** 2007. Viral oncogene-induced DNA damage  
595 response is activated in Kaposi sarcoma tumorigenesis. *PLoS Pathog* **3**:1348-1360.
- 596 37. **Wu CC, Liu MT, Chang YT, Fang CY, Chou SP, Liao HW, Kuo KL, Hsu SL, Chen YR, Wang PW,**  
597 **Chen YL, Chuang HY, Lee CH, Chen M, Wayne Chang WS, Chen JY.** 2010. Epstein-Barr virus  
598 DNase (BGLF5) induces genomic instability in human epithelial cells. *Nucleic Acids Res*  
599 **38**:1932-1949.



- 600 38. **Xiao Y, Chen J, Liao Q, Wu Y, Peng C, Chen X.** 2013. Lytic infection of Kaposi's sarcoma-  
601 associated herpesvirus induces DNA double-strand breaks and impairs non-homologous end  
602 joining. *J Gen Virol* **94**:1870-1875.
- 603 39. **Nikitin PA, Luftig MA.** 2011. At a crossroads: human DNA tumor viruses and the host DNA  
604 damage response. *Future Virol* **6**:813-830.
- 605 40. **Nikitin PA, Luftig MA.** 2012. The DNA damage response in viral-induced cellular  
606 transformation. *Br J Cancer* **106**:429-435.
- 607 41. **Keles H, Fidan AF, Cigerci IH, Kucukkurt I, Karadas E, Dundar Y.** 2010. Increased DNA  
608 damage and oxidative stress in chickens with natural Marek's disease. *Vet Immunol*  
609 *Immunopathol* **133**:51-58.
- 610 42. **Dorange F, El Mehdaoui S, Pichon C, Coursaget P, Vautherot JF.** 2000. Marek's disease virus  
611 (MDV) homologues of herpes simplex virus type 1 UL49 (VP22) and UL48 (VP16) genes: high-  
612 level expression and characterization of MDV-1 VP22 and VP16. *J Gen Virol* **81**:2219-2230.
- 613 43. **Denesvre C, Remy S, Trapp-Fragnet L, Smith LP, Georgeault S, Vautherot JF, Nair V.** 2015.  
614 Marek's disease virus undergoes complete morphogenesis after reactivation in T-  
615 lymphoblastoid cell line transformed by recombinant fluorescent marker virus. *J Gen Virol*  
616 doi:10.1099/jgv.0.000354;DOI: 10.1099/jgv.1090.000354.
- 617 44. **Pratt WD, Morgan RW, Schat KA.** 1992. Characterization of reticuloendotheliosis virus-  
618 transformed avian T-lymphoblastoid cell lines infected with Marek's disease virus. *J Virol*  
619 **66**:7239-7244.
- 620 45. **Blondeau C, Marc D, Courvoisier K, Vautherot JF, Denesvre C.** 2008. Functional homologies  
621 between avian and human alphaherpesvirus VP22 proteins in cell-to-cell spreading as  
622 revealed by a new cis-complementation assay. *J Virol* **82**:9278-9282.
- 623 46. **Jarosinski KW, Margulis NG, Kamil JP, Spatz SJ, Nair VK, Osterrieder N.** 2007. Horizontal  
624 transmission of Marek's disease virus requires US2, the UL13 protein kinase, and gC. *J Virol*  
625 **81**:10575-10587.
- 626 47. **Arumugaswami V, Kumar PM, Konjufca V, Dienglewicz RL, Reddy SM, Parcells MS.** 2009.  
627 Latency of Marek's disease virus (MDV) in a reticuloendotheliosis virus-transformed T-cell  
628 line. II: expression of the latent MDV genome. *Avian Dis* **53**:156-165.
- 629 48. **Jarosinski KW, Yunis R, O'Connell PH, Markowski-Grimsrud CJ, Schat KA.** 2002. Influence of  
630 genetic resistance of the chicken and virulence of Marek's disease virus (MDV) on nitric oxide  
631 responses after MDV infection. *Avian Dis* **46**:636-649.
- 632 49. **Lebailly P, Devaux A, Pottier D, De Meo M, Andre V, Baldi I, Severin F, Bernaud J, Durand B,**  
633 **Henry-Amar M, Gauduchon P.** 2003. Urine mutagenicity and lymphocyte DNA damage in  
634 fruit growers occupationally exposed to the fungicide captan. *Occup Environ Med* **60**:910-  
635 917.
- 636 50. **Ding AH, Nathan CF, Stuehr DJ.** 1988. Release of reactive nitrogen intermediates and  
637 reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of  
638 activating cytokines and evidence for independent production. *J Immunol* **141**:2407-2412.
- 639 51. **Walker JV, Nitiss JL.** 2002. DNA topoisomerase II as a target for cancer chemotherapy.  
640 *Cancer Invest* **20**:570-589.
- 641 52. **Barzilai A, Yamamoto K.** 2004. DNA damage responses to oxidative stress. *DNA Repair*  
642 (Amst) **3**:1109-1115.
- 643 53. **Phoa N, Epe B.** 2002. Influence of nitric oxide on the generation and repair of oxidative DNA  
644 damage in mammalian cells. *Carcinogenesis* **23**:469-475.
- 645 54. **Calnek BW, Schat KA, Ross LJ, Chen CL.** 1984. Further characterization of Marek's disease  
646 virus-infected lymphocytes. II. In vitro infection. *Int J Cancer* **33**:399-406.
- 647 55. **Shek WR, Calnek BW, Schat KA, Chen CH.** 1983. Characterization of Marek's disease virus-  
648 infected lymphocytes: discrimination between cytolytically and latently infected cells. *J Natl*  
649 *Cancer Inst* **70**:485-491.
- 650 56. **Palmai-Pallag T, Bachrati CZ.** 2014. Inflammation-induced DNA damage and damage-induced  
651 inflammation: a vicious cycle. *Microbes Infect* **16**:822-832.

- 652 57. **Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ.** 2000. Inflammatory cytokines induce DNA  
653 damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent  
654 mechanism. *Cancer Res* **60**:184-190.
- 655 58. **Jaiswal H, Lindqvist A.** 2015. Bystander communication and cell cycle decisions after DNA  
656 damage. *Front Genet* **6**:63.
- 657 59. **Elliott G, O'Hare P.** 1997. Intercellular trafficking and protein delivery by a herpesvirus  
658 structural protein. *Cell* **88**:223-233.
- 659 60. **Wu F, Long J, Wang S, Xing J, Li M, Zheng C.** 2012. Live cell imaging fails to support viral-  
660 protein-mediated intercellular trafficking. *Arch Virol* **157**:1383-1386.
- 661 61. **Xue X, Huang J, Wang H.** 2014. The study of the intercellular trafficking of the fusion proteins  
662 of herpes simplex virus protein VP22. *PLoS One* **9**:e100840.
- 663 62. **Djeraba A, Bernardet N, Dambrine G, Quere P.** 2000. Nitric oxide inhibits Marek's disease  
664 virus replication but is not the single decisive factor in interferon-gamma-mediated viral  
665 inhibition. *Virology* **277**:58-65.
- 666 63. **Xing Z, Schat KA.** 2000. Inhibitory effects of nitric oxide and gamma interferon on in vitro and  
667 in vivo replication of Marek's disease virus. *J Virol* **74**:3605-3612.
- 668 64. **Karanjawala ZE, Murphy N, Hinton DR, Hsieh CL, Lieber MR.** 2002. Oxygen metabolism  
669 causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA  
670 double-strand break repair mutants. *Curr Biol* **12**:397-402.
- 671 65. **Weitzman MD, Lilley CE, Chaurushiya MS.** 2010. Genomes in conflict: maintaining genome  
672 integrity during virus infection. *Annu Rev Microbiol* **64**:61-81.
- 673 66. **Guo Z, Deshpande R, Paull TT.** 2010. ATM activation in the presence of oxidative stress. *Cell*  
674 *Cycle* **9**:4805-4811.
- 675 67. **Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT.** 2010. ATM activation by oxidative stress.  
676 *Science* **330**:517-521.
- 677 68. **E X, Pickering MT, Debatis M, Castillo J, Lagadinos A, Wang S, Lu S, Kowalik TF.** 2011. An  
678 E2F1-mediated DNA damage response contributes to the replication of human  
679 cytomegalovirus. *PLoS Pathog* **7**:e1001342.
- 680 69. **Kudoh A, Fujita M, Zhang L, Shirata N, Daikoku T, Sugaya Y, Isomura H, Nishiyama Y,**  
681 **Tsurumi T.** 2005. Epstein-Barr virus lytic replication elicits ATM checkpoint signal  
682 transduction while providing an S-phase-like cellular environment. *J Biol Chem* **280**:8156-  
683 8163.
- 684 70. **Shirata N, Kudoh A, Daikoku T, Tatsumi Y, Fujita M, Kiyono T, Sugaya Y, Isomura H, Ishizaki**  
685 **K, Tsurumi T.** 2005. Activation of ataxia telangiectasia-mutated DNA damage checkpoint  
686 signal transduction elicited by herpes simplex virus infection. *J Biol Chem* **280**:30336-30341.
- 687 71. **Bohgaki T, Bohgaki M, Hakem R.** 2010. DNA double-strand break signaling and human  
688 disorders. *Genome Integr* **1**:15.
- 689 72. **Bill CA, Summers J.** 2004. Genomic DNA double-strand breaks are targets for hepadnaviral  
690 DNA integration. *Proc Natl Acad Sci U S A* **101**:11135-11140.
- 691 73. **Chen Y, Williams V, Filippova M, Filippov V, Duerksen-Hughes P.** 2014. Viral carcinogenesis:  
692 factors inducing DNA damage and virus integration. *Cancers (Basel)* **6**:2155-2186.
- 693

694 **FIGURE LEGENDS**

695 **Figure 1. Induction of DNA damage in MDV lytically infected cells.** CESC's were infected  
696 with  $10^4$  pfu of recEGFPVP22. (A) DNA damage analysis in mock- or recEGFPVP22-  
697 infected CESC's. At 4 dpi, EGFP-positive and -negative cells were sorted by flow cytometry  
698 and DNA damage was analyzed from  $2 \times 10^5$  cells by alkaline comet assays. Two slides per  
699 comet assays were prepared for each condition and analyzed using the CometScore software.  
700 Results are presented as the mean of OTM score ( $\pm$  SD; \*\*\* $p < 0.001$ ) and representative  
701 images of comets are shown as photographs. (B) Frequency distribution of the comets with  
702 respect to their OTM value. (C) Expression and localization of  $\gamma$ H2AX in CESC's infected  
703 with recEGFPVP22. At 4 dpi, mock- and recEGFPVP22-infected CESC's were subjected to  
704 immunofluorescence using a mouse anti- $\gamma$ H2AX monoclonal antibody and an AlexaFluor  
705 594-conjugated secondary antibody (red). Nuclei were stained with Hoechst 33342 (blue) and  
706 infected cells expressing the EGFP-tagged VP22 were directly visualized by fluorescent  
707 microscopy (green).

708 **Figure 2. DNA damage induction enhances MDV replication.** (A-D) CESC's were infected  
709 with recEGFPVP22 and treated at 6 hpi with etoposide (ETP), Bleomycin, hydroxyurea (HU)  
710 and  $H_2O_2$  at the indicated concentrations or with DMSO or  $H_2O$  (as negative controls). (A-B)  
711 At 24, 48, 72, and 96 hpi, DNA was extracted from cells treated with ETP and MDV  
712 replication was assessed using qPCR. For each group, the number of MDV genome copies  
713 (corresponding to ICP4 copies number) was normalized to  $10^6$  cells (estimated by the iNOS  
714 copies number). (A) Representative growth curve from a total of 3 independent experiments.  
715 Means of qPCR triplicates are indicated ( $\pm$  SD). (B) Fold change in MDV copies in ETP-  
716 treated cells relative to DMSO-treated cells (\*\* $p < 0.05$ ). (C) Number of cells lytically infected  
717 with MDV upon ETP treatment. The percentage of viable GFP positive infected cells was  
718 determined at 96 hpi by FACS. Viable cells were detected using the viability dye eFluor-780.

719 Means are represented as bars ( $\pm$  SD; \* $p < 0.05$ ). (D) Effect of ETP on MDV plaques size.  
720 Images of fluorescent MDV plaques were taken and plaque sizes measured at 48 hpi. Means  
721 are presented as histograms ( $\pm$  SD; \* $p < 0.05$ ; \*\*\* $p < 0.001$ ). (E) Impact of ETP induced DNA  
722 damage on MDV replication in RECC-CU91 T-cells. (E) RECC-CU91 cells were infected  
723 with RB-1B\_TK-GFP and treated with 0.02 and 0.1  $\mu$ M of ETP or with DMSO (as a negative  
724 control). At 24, 48 and 72 hpi, MDV genome copy number was quantified by qPCR and data  
725 shown as a fold change ( $\pm$  SD) relative to DMSO-treated cells.

726 **Figure 3. MDV replication induces production of ROS and NO.** CESC's were mock-  
727 infected or infected with recEGFPVP22. (A) ROS accumulation in supernatant of mock- and  
728 recEGFPVP22-infected cells. At 24, 48, 72, and 96 hpi, supernatants of mock- and  
729 recEGFPVP22-infected cells were collected, and H<sub>2</sub>O<sub>2</sub> accumulation was quantified using the  
730 ROS-Glo™ kit (Promega). Results were normalized to RLU values obtained from mock-  
731 infected cells and expressed as means ( $\pm$  SD). (B) NO production in supernatant of mock- and  
732 recEGFPVP22-infected cells. At indicated time points, supernatants of mock- and  
733 recEGFPVP22-infected cells were collected, and nitrite accumulation was quantified using  
734 the Griess reaction. Absorbance values (at 540 nm) obtained from supernatant of infected  
735 cells were reported to these from mock-infected cells and expressed as means ( $\pm$  SD). (C)  
736 Expression of inducible nitric oxide synthase (iNOS) in MDV infected cells. Total mRNA  
737 was isolated from mock- and MDV infected CESC's at the time point indicated and qRT-PCR  
738 were performed with iNOS specific primers. Results were normalized to GAPDH expression  
739 and expressed as mRNA fold change compared to expression of iNOS in mock-infected cells  
740 ( $\pm$  SD).

741 **Figure 4. Induction of DNA damage in PBMCs of chickens infected with MDV.** Specific  
742 pathogen free (SPF) susceptible white leghorn chicks (B13/B13 haplotype) were inoculated  
743 intramuscularly with 1,000 pfu of the very virulent MDV strain vRB-1B. DNA damage onset

744 in PBMCs was assessed in 10 non-infected chickens (circles) and 13 birds infected with vRB-  
745 1B (triangles). Blood was collected from all birds at indicated time points. (A) DNA damage  
746 analysis in PBMCs isolated from mock- and vRB-1B infected chickens by alkaline comet  
747 assays. Two slides per comet assays were prepared for each animal at each time point. A  
748 minimum of 50 comets were observed and further analyzed on each replicate slide using the  
749 CometScore software. Results are presented as dot plot, each dot representing an animal and  
750 the mean of OTM for each group is indicated as a bar (\*\*\* $p < 0.001$ ). (B) Viral load estimated  
751 after DNA extraction from whole blood and quantification of MDV genome copies using  
752 qPCR. For each group, the number of ICP4 copies in the MDV genome was normalized to  
753  $10^6$  copies of cellular genome estimated by the detection of iNOS copies. The medians copy  
754 numbers are indicated as a bar. (C) Meq mRNA expression upon MDV infection. Total RNA  
755 was extracted from PBMCs isolated from blood of birds infected with vRB-1B. Quantitative  
756 RT-PCRs were performed in order to detect the mRNA expression of Meq. Gene expression  
757 was normalized to GAPDH expression and fold changes are presented as box plot (Min/max).

758 **Figure 5. Role of VP22 and DNA damage in MDV-mediated oncogenicity in chickens.**

759 SPF white leghorn chicks were inoculated with 1,500 pfu of vRB-1B, vRB-1B EGFP22, or  
760 vRB-1B 22EGFP. Blood was collected from all birds at indicated time points and PBMCs  
761 were isolated. (A) DNA damage was quantified from  $2 \times 10^5$  PBMCs using the alkaline comet  
762 assay. Results are presented as dot plots, each dot representing an animal. For each group, the  
763 median of the OTM is indicated as a bar (\*\*\* $p < 0.001$ ) (B). MDV viral load was evaluated by  
764 qPCR on DNA extracted from PBMCs. The number of MDV copies per  $10^6$  cells is presented  
765 as a dot plot, each dot representing an animal. For each group, the median is indicated as a bar  
766 (\* $p < 0.05$ ; \*\* $p < 0.005$ ).

767

768 **Figure 6. DNA damage during MDV reactivation.**

769 3867K cells undergoing MDV lytic replication were sorted by cytometry on the basis of the  
770 expression of the UL47 gene tagged with EGFP. (A) DNA damage analysis in lytically  
771 (GFP+) and latently (GFP-) infected cells. The alkaline comet assay was performed on EGFP-  
772 positive and -negative sorted cells. Results are presented as the mean of OTM ( $\pm$  SD;  
773 \*\*\* $p < 0.001$ ) and representative comets images are shown below. (B) Frequency distribution  
774 of the comets with respect to their OTM value. (C-E) Effect of DNA damaging  
775 pharmacological agents on MDV reactivation. 3867K cells were treated with etoposide  
776 (ETP), bleomycin, hydroxyurea (HU) or  $H_2O_2$  at the indicated concentrations for 48 hours.  
777 DMSO and  $H_2O$  were added to culture media as negative controls. (C) MDV replication was  
778 evaluated by quantifying the mRNA expression of the immediate-early gene ICP4 by qRT-  
779 PCR. ICP4 expression was normalized to the expression of GAPDH and results are presented  
780 as means ( $\pm$  SD; \*\* $p < 0.005$ ). (D-E) Number of MDV reactivated 3867K cells. The  
781 percentage of GFP positive cells (expressing the EGFP-tagged UL47 protein) was determined  
782 48 h post-treatment by cytometry specifically in viable cells labeled using the viability dye  
783 eFluor-780. Means are represented as bars ( $\pm$  SD; \* $p < 0.05$ ). Results are representative of 3  
784 independent experiments realized in triplicates.



Target		Sequences	Accession Number
ICP4	For	5'TTTCTAGCAAGGAGCGACGC3'	NC_002229.3
	Rev	5'CTGACTTGCGCTTACGGGAA3'	
Meq	For	5'GTCCCCCCTCGATCTTTCTC3'	AY571783.1
	Rev	5'CGTCTGCTTCCTGCGTCTTC3'	
iNOS	For	5'TACTGCGTGTCTTTCAACG3'	U46504
	Rev	5'CCCATTCTTCTCCAACCTC3'	
GAPDH	For	5'TGATGATATCAAGAGGGTAGTGAAG3'	K01458
	Rev	5'TCCTTGGATGCCATGTGGACCAT3'	

785 **Table 1. List of primer pairs used for (q)RT-PCR**


786

Treatment	Concentration (μM)	Mean ICP4/10 <sup>6</sup> iNOS copies
H <sub>2</sub> O		(1.46±0,22)×10 <sup>8</sup>
Bleomycin	0.125	(1.33±0,05)×10 <sup>8</sup>
	0.25	(2.25±0,04)×10 <sup>8</sup>
	0.5	(2.16±0,14)×10 <sup>8</sup>
	1	(2.47±0,33)×10 <sup>8</sup>
	10	(2.55±0,03)×10 <sup>8</sup>
Hydroxyurea	25	(2.6±0,005)×10 <sup>8</sup>
	50	(1.76±0,03)×10 <sup>8</sup>
	75	(1.83±0,25)×10 <sup>8</sup>
	12.5	(1.91±0,009)×10 <sup>8</sup>
H <sub>2</sub> O <sub>2</sub>	25	(1.6±0,03)×10 <sup>8</sup>
	50	(1.38±0,05)×10 <sup>8</sup>
	100	(2.12±0,23)×10 <sup>8</sup>

787 **Table 2. Effect of DNA damage inducers on MDV replication in CESC**

788

Figure 1




**Figure 1. Induction of DNA damage in MDV lytically infected cells.** CESC cells were infected with  $10^4$  pfu of recEGFPVP22. (A) DNA damage analysis in mock- or recEGFPVP22-infected CESC cells. At 4 dpi, EGFP-positive and -negative cells were sorted by flow cytometry and DNA damage was analyzed from  $2 \times 10^5$  cells by alkaline comet assays. Two slides per comet assays were prepared for each condition and analyzed using the CometScore software. Results are presented as the mean of OTM score ( $\pm$  SD; \*\*\* $p < 0.001$ ) and representative images of comets are shown as photographs. (B) Frequency distribution of the comets with respect to their OTM value. (C) Expression and localization of  $\gamma$ H2AX in CESC cells infected with recEGFPVP22. At 4 dpi, mock- and recEGFPVP22-infected CESC cells were subjected to immunofluorescence using a mouse anti- $\gamma$ H2AX monoclonal antibody and an AlexaFluor 594-conjugated secondary antibody (red). Nuclei were stained with Hoechst 33342 (blue) and infected cells expressing the EGFP-tagged VP22 were directly visualized by fluorescent microscopy (green).

Comment citer ce document :

Bencherit, D., Rémy, S., Le Vern, Y., Vychodil, T., Bertzbach, L. D., Kaufer, B. B., Denesvre, C., Trapp-Fraget, L. (Auteur de correspondance) (2017). Induction of DNA damages upon Marek's disease virus infection: implication in viral replication and pathogenesis. *Journal of Virology*. 91 (24). 1-36. DOI : 10.1128/JVI.01658-17




Figure 2




**Figure 2. DNA damage induction enhances MDV replication.** (A-D) CESC cells were infected with recEGFPVP22 and treated at 6 hpi with etoposide (ETP), Bleomycin, hydroxyurea (HU) and H<sub>2</sub>O<sub>2</sub> at the indicated concentrations or with DMSO or H<sub>2</sub>O (as negative controls). (A-B) At 24, 48, 72, and 96 hpi, DNA was extracted from cells treated with ETP and MDV replication was assessed using qPCR. For each group, the number of MDV genome copies (corresponding to ICP4 copies number) was normalized to 10<sup>6</sup> cells (estimated by the iNOS copies number). (A) Representative growth curve from a total of 3 independent experiments. Means of qPCR triplicates are indicated ( $\pm$  SD). (B) Fold change in MDV copies in ETP-treated cells relative to DMSO-treated cells (\*\*p<0.05). (C) Number of cells lytically infected with MDV upon ETP treatment. The percentage of viable GFP positive infected cells was determined at 96 hpi by FACS. Viable cells were detected using the viability dye eFluor-780. Means are represented as bars ( $\pm$  SD; \*p<0.05). (D) Effect of ETP on MDV plaque size. Images of fluorescent MDV plaques were taken and plaque sizes measured at 48 hpi. Means are presented as histograms ( $\pm$  SD; \*p<0.05; \*\*\*p<0.001). (E) Impact of ETP induced DNA damage on MDV replication in RECC-CU91 T-cells. (E) RECC-CU91 cells were infected with RB-1B TK-GFP and treated with 0.02 and 0.1  $\mu$ M of ETP or with DMSO (as a negative control). At 24, 48 and 72 hpi, MDV genome copy number was quantified by qPCR and data shown as a fold change ( $\pm$  SD) relative to DMSO-treated cells.

Figure 3



**Figure 3. MDV replication induces production of ROS and NO.** CESC were mock-infected or infected with recEGFPVP22. (A) ROS accumulation in supernatant of mock- and recEGFPVP22-infected cells. At 24, 48, 72, and 96 hpi, supernatants of mock- and recEGFPVP22-infected cells were collected, and H<sub>2</sub>O<sub>2</sub> accumulation was quantified using the ROS-GloTM kit (Promega). Results were normalized to RLU values obtained from mock-infected cells and expressed as means ( $\pm$  SD). (B) NO production in supernatant of mock- and recEGFPVP22-infected cells. At indicated time points, supernatants of mock- and recEGFPVP22-infected cells were collected, and nitrite accumulation was quantified using the Griess reaction. Absorbance values (at 540 nm) obtained from supernatant of infected cells were reported to these from mock-infected cells and expressed as means ( $\pm$  SD). (C) Expression of inducible nitric oxide synthase (iNOS) in MDV infected cells. Total mRNA was isolated from mock- and MDV infected CESC at the time point indicated and qRT-PCR were performed with iNOS specific primers. Results were normalized to GAPDH expression and expressed as mRNA fold change compared to expression of iNOS in mock-infected cells ( $\pm$  SD).

Figure 4



**Figure 4. Induction of DNA damage in PBMCs of chickens infected with MDV.** Specific pathogen free (SPF) susceptible white leghorn chicks (B13/B13 haplotype) were inoculated intramuscularly with 1,000 pfu of the very virulent MDV strain vRB-1B. DNA damage onset in PBMCs was assessed in 10 non-infected chickens (circles) and 13 birds infected with vRB-1B (triangles). Blood was collected from all birds at indicated time points. (A) DNA damage analysis in PBMCs isolated from mock- and vRB-1B infected chickens by alkaline comet assays. Two slides per comet assays were prepared for each animal at each time point. A minimum of 50 comets were observed and further analyzed on each replicate slide using the CometScore software. Results are presented as dot plot, each dot representing an animal and the mean of OTM for each group is indicated as a bar (\*\*\*) $p < 0.001$ ). (B) Viral load estimated after DNA extraction from whole blood and quantification of MDV genome copies using qPCR. For each group, the number of ICP4 copies in the MDV genome was normalized to 10<sup>6</sup> copies of cellular genome estimated by the detection of iNOS copies. The median copy numbers are indicated as a bar. (C) Meq mRNA expression upon MDV infection. Total RNA was extracted from PBMCs isolated from blood of birds infected with vRB-1B. Quantitative RT-PCRs were performed in order to detect the mRNA expression Meq. Gene expression was normalized to GAPDH expression and fold changes are presented as box plot (Min/max).

Comment citer ce document :

Bencherit, D., Rémy, S., Le Vern, Y., Vychodil, T., Bertzbach, L. D., Kaufer, B. B., Denesvre, C., Trapp-Fragnet, L. (Auteur de correspondance) (2017). Induction of DNA damages upon Marek's disease virus infection: implication in viral replication and pathogenesis. *Journal of Virology*, 91 (24), 1-36. DOI : 10.1128/JVI.01658-17

Figure 5





Figure 6



**Figure 6. DNA damage during MDV reactivation.** 3867(K) cells undergoing MDV lytic replication were sorted by cytometry on the basis of the expression of the UL47 gene tagged with EGFP. (A) DNA damage analysis in lytically (GFP+) and latently (GFP-) infected cells. The alkaline comet assay was performed on EGFP-positive and -negative sorted cells. Results are presented as the mean of OTM ( $\pm$  SD; \*\*\* $p$ <0.001) and representative comets images are shown below. (B) Frequency distribution of the comets with respect to their OTM value. (C-E) Effect of DNA damaging pharmacological agents on MDV reactivation. 3867(K) cells were treated with etoposide (ETP), bleomycin, hydroxyurea (HU) or H<sub>2</sub>O<sub>2</sub> at the indicated concentrations for 48 hours. DMSO and H<sub>2</sub>O were added to culture media as negative controls. (C) MDV replication was evaluated by quantifying the mRNA expression of the immediate-early gene ICP4 by qRT-PCR. ICP4 expression was normalized to the expression of GAPDH and results are presented as means ( $\pm$  SD; \*\* $p$ <0.005). (D-E) Number of MDV reactivated 3867(K) cells. The percentage of GFP positive cells (expressing the EGFP-tagged UL47 protein) was determined 48 h post-treatment by cytometry specifically in viable cells labeled using the viability dye eFluor-780. Means are represented as bars ( $\pm$  SD; \* $p$ <0.05). Results are representative of 3 independent experiments realized in triplicates.

Comment citer ce document :

Bencherit, D., Rémy, S., Le Vern, Y., Vychodil, T., Bertzbach, L. D., Kaufer, B. B., Denesvre, C., Trapp-Fraget, L. (Auteur de correspondance) (2017). Induction of DNA damages upon Marek's disease virus infection: implication in viral replication and pathogenesis. *Journal of Virology*. 91 (24). 1-36. DOI : 10.1128/JVI.01658-17